WO2014102741A3 - Pharmaceutical dosage form - Google Patents

Pharmaceutical dosage form Download PDF

Info

Publication number
WO2014102741A3
WO2014102741A3 PCT/IB2013/061366 IB2013061366W WO2014102741A3 WO 2014102741 A3 WO2014102741 A3 WO 2014102741A3 IB 2013061366 W IB2013061366 W IB 2013061366W WO 2014102741 A3 WO2014102741 A3 WO 2014102741A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
pharmaceutical dosage
api
shell
swellable polymer
Prior art date
Application number
PCT/IB2013/061366
Other languages
French (fr)
Other versions
WO2014102741A2 (en
Inventor
Viness Pillay
Yahya Essop Choonara
Lisa Claire Du Toit
Pradeep Kumar
Angus Rolland HIBBINS
Original Assignee
University Of The Witwatersrand, Johannesburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of The Witwatersrand, Johannesburg filed Critical University Of The Witwatersrand, Johannesburg
Publication of WO2014102741A2 publication Critical patent/WO2014102741A2/en
Publication of WO2014102741A3 publication Critical patent/WO2014102741A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Abstract

The invention relates to a pharmaceutical dosage form for delivery of, at a target site in a human or animal body, an active pharmaceutical ingredient (API), said pharmaceutical dosage form comprising a shell defining therein an outlet; a polymeric matrix having at least one API, the polymeric matrix received within the shell; and a swellable polymer body located within the shell, wherein the swellable polymer body is pH responsive, such that in use, exposure of the body to a medium of increasing pH causes an increase in swelling and an increase in volume of the swellable polymer body, which in turn, facilitates displacement of the matrix through the outlet toward the target site for delivery of the API.
PCT/IB2013/061366 2012-12-28 2013-12-27 Pharmaceutical dosage form WO2014102741A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA2012/07430 2012-12-28
ZA201207430 2012-12-28

Publications (2)

Publication Number Publication Date
WO2014102741A2 WO2014102741A2 (en) 2014-07-03
WO2014102741A3 true WO2014102741A3 (en) 2014-12-04

Family

ID=50070628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/061366 WO2014102741A2 (en) 2012-12-28 2013-12-27 Pharmaceutical dosage form

Country Status (1)

Country Link
WO (1) WO2014102741A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180193621A1 (en) * 2015-06-30 2018-07-12 Entrega Inc. Device for oral delivery of active agents
CN106265530B (en) * 2016-08-19 2018-11-02 浙江汇能生物股份有限公司 A kind of Mercaptamine pre-mixing agent and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US4959218A (en) * 1988-03-25 1990-09-25 Alza Corporation Method for delivering somatotropin to an animal
US6004582A (en) * 1997-05-30 1999-12-21 Laboratorios Phoenix U.S.A, Inc. Multi-layered osmotic device
US6524305B1 (en) * 1997-07-25 2003-02-25 Alza Corporation Osmotic delivery system flow modulator apparatus and method
WO2004010981A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
WO2007044234A1 (en) * 2005-10-07 2007-04-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
WO2007140416A2 (en) * 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATA7997A (en) 1997-01-21 1998-03-15 Bernkop Schnuerch Andreas METHOD FOR PRODUCING CHITOSAN ETHYLENE DIAMINE TETRAACETATE CONJUGATES
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US8348930B2 (en) 2005-07-01 2013-01-08 Microlin, Llc Fluid delivery device with a diffusion membrane and electrochemical pump
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US4959218A (en) * 1988-03-25 1990-09-25 Alza Corporation Method for delivering somatotropin to an animal
US6004582A (en) * 1997-05-30 1999-12-21 Laboratorios Phoenix U.S.A, Inc. Multi-layered osmotic device
US6524305B1 (en) * 1997-07-25 2003-02-25 Alza Corporation Osmotic delivery system flow modulator apparatus and method
WO2004010981A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
WO2007044234A1 (en) * 2005-10-07 2007-04-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
WO2007140416A2 (en) * 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MALATERRE V ET AL: "Oral osmotically driven systems: 30 years of development and clinical use", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 73, no. 3, 1 November 2009 (2009-11-01), pages 311 - 323, XP026736254, ISSN: 0939-6411, [retrieved on 20090712], DOI: 10.1016/J.EJPB.2009.07.002 *

Also Published As

Publication number Publication date
WO2014102741A2 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
NZ704011A (en) Abuse deterrent pharmaceutical compositions for controlled release
BRPI0719060A2 (en) COMPOUND, PRODUCT, PHARMACEUTICAL AGENT, METHODS TO INHIBIT AN ANGIOTENSIN II RECEIVER AND / OR ACTIVATE A PEROXISOMAL ACTIVATED RECEIVER, AND TO PREVENT OR TREAT DISEASE OR CONDITION, AND, USE OF A COMPOUND
WO2016004048A3 (en) Targeted conjugates and particles and formulations thereof
WO2012109022A3 (en) Medical fluid delivery device programming
WO2010035273A3 (en) Novel gastroretentive delivery system
BRPI0816887A2 (en) Drug delivery system, contraceptive methods, to concurrently provide contraception and treat or prevent a sexually transmitted disease, and to manufacture the three-layer drug delivery system, and use of the drug delivery system.
EP4233978A3 (en) Oral delivery of active drug substances
WO2012091954A3 (en) Median lobe destruction apparatus and method
BRPI0810899A2 (en) FORMULATION OF ACTIVATED PLGA NANOParticles loaded with ACTIVE AGENT FOR DIRECTIONAL ANTICANETIC NANO-THERAPEUTIC SUBSTANCES.
WO2010135418A3 (en) Implantable medical devices for therapeutic agent delivery
IT1395128B1 (en) DEVICE / SYSTEM FOR MIXING LIQUIDS, DRUGS AND SOLUTIONS BEFORE ADMINISTRATION INSIDE THE HUMAN BODY
BRPI0819115A2 (en) Liquid aqueous formulation, nasal drug dispensing device or dosage cartridge, and use of solubilizing agent.
WO2011067667A3 (en) Fexofenadine microcapsules and compositions containing them
CL2014003148A1 (en) Aqueous pharmaceutical composition containing a biological therapeutic agent and guanidine or a guanidine derivative and an injection that includes the composition.
WO2011143118A3 (en) Alcohol-resistant formulations
MX2017003561A (en) Compositions and methods for cannabinoid coatings for use in drug delivery.
EA201692392A1 (en) NEW MEDICINE FORM OF MELOXYCAM
TR201010683A1 (en) Vildagliptin formulations.
EA201170117A1 (en) ANTIALLERGICAL BIOPOLYMERS OF MARINE ORIGIN
WO2014102741A3 (en) Pharmaceutical dosage form
WO2012172433A3 (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient
WO2014075203A8 (en) Nanoparticles with biodegradable and biocompatible polymer plga, loaded with the drug for human use pentoxifylline
UA113966C2 (en) WATER LIQUID PHARMACEUTICAL COMPOSITION CONTAINING ARBECACIN
WO2012052834A3 (en) Multiple unit particulate system comprising metoprolol succinate
MX2016010892A (en) Agent for improving or preventing progression of chronic kidney disease.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13828884

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase

Ref document number: 13828884

Country of ref document: EP

Kind code of ref document: A2